Enzyme Inhibitors Could Calm Overactive Immune Cells
Researchers at the University of Pittsburgh target lysine demethylases to dampen inflammatory macrophages in laboratory studies.
Updated on Nov. 19, 2026 in Science

Researchers identified lysine demethylases as potential therapeutic targets for reducing inflammation driven by macrophages, a type of immune cell. In laboratory experiments, pretreating macrophages with the inhibitors n-octyl-IOX1 or PB-IT reduced inflammatory cytokine and Nlrp3 inflammasome expression after bacterial lipopolysaccharide exposure.
Why it matters
Excessive macrophage inflammation contributes to conditions such as sepsis, influenza-associated inflammation and long COVID-19, where elevated KDM expression was observed. A delivery approach using lipidoid nanoparticles aimed at directing inhibitors specifically to macrophages could help limit effects on other cells.
The findings come from laboratory cell-culture experiments with bone marrow-derived macrophages and mouse models, supplemented by open-source datasets showing higher KDM expression in alveolar macrophages from patients with long COVID-19 and bacterial sepsis. Whether these laboratory results translate to human patients has not been established.
The players
University of Pittsburgh
A public research university in Pittsburgh, Pennsylvania, with a large biomedical research enterprise and the institution where the lead researcher works.
The details
Lysine demethylases remove inhibitory histone methylation during immune cell development and differentiation. In the study, pretreatment of macrophages with n-octyl-IOX1, a pan-KDM inhibitor, or PB-IT, a KDM5-specific inhibitor, before bacterial lipopolysaccharide exposure reduced inflammatory signaling, and lipidoid nanoparticles were used as a proof-of-concept method to deliver n-octyl-IOX1 specifically to macrophages.
Timeline
The study was reported in an article published on asbmb.org on November 19, 2026.
The Big Picture
The work extends a growing line of research that treats epigenetic enzymes as levers for controlling macrophage activity rather than blocking immune responses broadly. Its emphasis on delivering inhibitors selectively to macrophages addresses a longstanding challenge in translating epigenetic drugs into safe therapies.
The approach is at an early research stage, so no treatments are available to patients yet. If later studies confirm efficacy and safety, targeted macrophage therapies could eventually reach clinical use for inflammatory conditions.
The takeaway
Targeted delivery is central to making epigenetic drugs safer, so readers following medical advances should watch for follow-up studies testing these approaches in sepsis, influenza and long COVID-19.
Further reading
For related coverage, explore the Life Sciences section.
Source note: This article includes information reported by Asbmb.






